Document Detail


Reversal effect of Raf-1/Mdr-1 siRNAs co-transfection on multidrug resistance in KBv200 cell line.
MedLine Citation:
PMID:  19631573     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Multidrug resistance (MDR) is a major barrier for chemotherapy of many cancers. Mdr-1 plays a key role in the development of MDR as extensively verified. However, the role of Raf-1 overexpression in the development of multidrug resistance in human squamous carcinoma (KBv200) cells remains largely unknown. The aim of this study was to investigate the correlation of Raf-1 overexpression with the development of multidrug resistance in KBv200 cells. Furthermore, we explored the reversal effect of Raf-1 siRNA transfection and Raf-1/Mdr-1 siRNAs co-transfection on the multidrug resistance of KBv200 cells and potential mechanism of reversing the multidrug resistance. MTT and flow cytometry assay were used to investigate the reversal effect of single transfection with either Raf-1 or Mdr-1 siRNA and double transfection with Raf-1/Mdr-1 siRNAs to vincristine of KBv200 cells. RT-PCR, immunofluorescence and Western Blot were used to detect mRNA and protein expression of Raf-1 and multidrug-resistant gene Mdr-1. The results of gene detection showed that the expression levels of both Raf-1 and Mdr-1 were greatly decreased upon Raf-1 silencing alone or in combination with Mdr-1 silencing. Raf-1 or Mdr-1 siRNA single transfection could reverse the multidrug resistance of KBv200 cells effectively. Compared with single transfection, Raf-1/Mdr-1 siRNAs co-transfection can significantly reduce IC(50) values and increase the apoptotic rates of KBv200 cells. The above results suggested that Raf-1 gene may be a novel target for reversing the multidrug resistance of human squamous carcinoma cells. Raf-1/Mdr-1 siRNAs co-transfection might be a promising approach to abrogate the multidrug resistance of cancer cells. The potential mechanism may be via inhibiting the multidrug-resistant gene Mdr-1 expression efficiently.
Authors:
Yan Dong; Shujuan Shao; Jun Hu; Peiman Yang
Related Documents :
12588963 - Induction of a storage phenotype and abnormal intracellular localization of apical glyc...
7907333 - Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosp...
11467773 - Differences in association of the serine/threonine protein phosphatase pp-2a with micro...
Publication Detail:
Type:  Journal Article     Date:  2009-07-23
Journal Detail:
Title:  Oral oncology     Volume:  45     ISSN:  1879-0593     ISO Abbreviation:  Oral Oncol.     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-10-20     Completed Date:  2011-03-24     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9709118     Medline TA:  Oral Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  991-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Phytogenic / pharmacology
Blotting, Western
Carcinoma, Squamous Cell / drug therapy*,  metabolism
Cell Line, Tumor / drug effects
Drug Resistance, Multiple / drug effects*
Drug Resistance, Neoplasm / drug effects*
Flow Cytometry
Humans
P-Glycoprotein / drug effects*,  metabolism
Proto-Oncogene Proteins c-raf / drug effects*,  metabolism
RNA, Small Interfering / pharmacology*
Reverse Transcriptase Polymerase Chain Reaction
Vincristine / pharmacology
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/P-Glycoprotein; 0/RNA, Small Interfering; 57-22-7/Vincristine; EC 2.7.11.1/Proto-Oncogene Proteins c-raf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparing registration methods for mapping brain change using tensor-based morphometry.
Next Document:  Unmet information needs and preferences in newly diagnosed and surgically treated oral cavity cancer...